HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for :

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...

Related Keywords

China , Shanghai , Peking , Beijing , Denmark , Hong Kong , Lanzhou , Gansu , Chinese , Zhou Yi , Ben Atwell Alex Shaw , Liansheng Zhang , Elsevier Saunders , Fausto Nelson , Fengkui Zhang , Cotran Ramzi , Panmure Gordon , Annie Cheng , Kumar Vinay , Bing Han , Atholl Tweedie Freddy Crossley , Nelso Fausto , Mark Lee , Abbas Abulk Robbins , Robbins Stanley , Exchange Commission , China Limited , Lanzhou University Second Hospital , Stock Exchange Of Hong Kong , Linkedin , Nasdaq , Chinese Academy , Medical Sciences Blood Diseases Hospital , Medical Sciences Peking Union College , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , Senior Vice , Brad Miles , Ben Atwell , Alex Shaw , Freddy Crossley , Abbas Abul , Pharmacol Exp , Rev Clin , Nasdaq Hcm , Hutchmed China Limited ,